METHODS: We present the case of a 70-year-old Moroccan male patient diagnosed with non-small cell lung carcinoma initially metastatic to the pleura with an epithelial growth factor receptor mutation who received gefitinib in first line with a complete response, he subsequently presented with cerebral oligo-progression with extra cranial stability. The patient was started on osimertinib with unknown T790M status, as it was impossible to perform a cerebral biopsy, the evolution was characterized by a partial response followed by stereotactic radiotherapy then a complete response for 2 years.
CONCLUSIONS: We can discuss osimertinib as an option for patients with stage IV non-small cell lung cancer with brain oligo-progression on prior tyrosine kinase inhibitors and unknown T790M status, further studies are needed in this area.
方法:我们介绍了一名70岁的摩洛哥男性患者,该患者被诊断为非小细胞肺癌,最初转移到胸膜并伴有上皮生长因子受体突变,在一线接受吉非替尼治疗,完全缓解,随后,他出现了脑低聚进展,颅外稳定。患者开始服用奥希替尼,T790M状态未知,因为不可能进行脑活检,演变的特征是部分反应,然后是立体定向放射治疗,然后是2年的完全反应。
结论:我们可以讨论奥希替尼作为IV期非小细胞肺癌患者的一种选择,这些患者在接受过酪氨酸激酶抑制剂且T790M状态未知的情况下脑寡进展,这方面还需要进一步的研究。